Advanced Filters
noise

Rectal Disorders Clinical Trials

A listing of Rectal Disorders medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 686 clinical trials
Y Yanhong Deng, Doctor

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer

Colorectal cancer of Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) accounts for approximately 15% of all colorectal cancer patients, with a higher proportion in right colon cancer. Previous studies have found that colon cancer patients with dMMR/MSI-H cannot benefit from 5-fluorouracil (5-FU) adjuvant chemotherapy. Once patients have distant metastases, they are …

18 - 75 years of age All Phase 1/2
G GV20 Therapeutics

A Study of GV20-0251 in Patients With Solid Tumor Malignancies

This is a Phase 1 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.

18 years of age All Phase 1

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.

18 - 125 years of age All Phase 1
J Jennifer Lister, BSc CCRP

In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung

This study is investigating a new technique for delivering chemotherapy directly into the lungs at the time of surgery. Delivering chemotherapy directly to the lungs could potentially kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the …

18 - 70 years of age All Phase 1
M Megan Barrett

A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumors harboring a KRAS G12D-mutation.

18 years of age All Phase 1/2
D Donald Richards, MD

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)

This is an open-label multicenter, single-arm Phase II study of Fruquintinib in combination with FOLFIRI (leucovorin calcium (folinic acid), fluorouracil, and irinotecan) in participants with metastatic colorectal cancer (mCRC). The main goals of this study are to: Evaluate the efficacy of the combination of fruquintinib + FOLFIRI in the 2nd-line …

18 years of age All Phase 2
M Marie Grönroos-Korhonen

Laparoscopic Approach for Emergency Colon Resection

This is a randomized, controlled, parallel, multicenter trial to compare post-operative complications and long-term results between open and laparoscopic technique in emergency colorectal surgery.

18 - 100 years of age All Phase N/A
Z Zih-Yun Deng

Exercise Intervention to Improve Quality of Life in Patients With Colorectal Cancer

The purpose of this study was to explore the 12-week effectiveness of home exercise intervention for colorectal cancer patients in improving fatigue, sleep, muscle endurance, and quality of life. Explore the effect of "12-week home exercise intervention" in improving the fatigue of colorectal cancer patients. Explore the effect of "12-week …

20 years of age All Phase N/A
L Lingling Jiang

A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors

The goal of this clinical trial is to learn if the investigational drug (JR8603) is safe and effective in treating patients with solid tumors after their initial rounds of treatment with other drugs did not work.

18 years of age All Phase 1
W Wei Zhang

Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases

Recurrence of liver metastasis in colorectal cancer after R0 resection is mainly due to the invisible minimal residual disease, which are the main factors leading to metastasis and recurrence. Positive circulating tumor DNA (ctDNA) is the direct evidence of the minimal residual disease (MRD). In recent years, Chimeric Antigen Receptor …

18 - 75 years of age All Phase 1

Simplify language using AI